| Item Type | Name |
|
Concept
|
Antibodies, Bacterial
|
|
Concept
|
Antibodies, Viral
|
|
Concept
|
Antibodies, Monoclonal
|
|
Concept
|
Antibodies, Monoclonal, Humanized
|
|
Concept
|
Antibodies
|
|
Academic Article
|
Advances in the management of Crohn's disease: economic and clinical potential of infliximab.
|
|
Academic Article
|
Infliximab in Crohn's disease: first anniversary clinical experience.
|
|
Academic Article
|
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
|
|
Academic Article
|
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
|
|
Academic Article
|
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.
|
|
Academic Article
|
Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center.
|
|
Academic Article
|
Evolving medical therapies for ulcerative colitis.
|
|
Academic Article
|
Medical therapy for ulcerative colitis: the state of the art and beyond.
|
|
Academic Article
|
Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease.
|
|
Academic Article
|
American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.
|
|
Academic Article
|
American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.
|
|
Academic Article
|
Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery.
|
|
Academic Article
|
Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials.
|
|
Academic Article
|
What is the optimal maintenance treatment for ulcerative colitis?
|
|
Academic Article
|
Infliximab decreases resource use among patients with Crohn's disease.
|
|
Academic Article
|
Infliximab in ulcerative colitis: is there a placebo (effect) in the house?
|
|
Academic Article
|
Infliximab at 5 years--tweaking the recipe for success?
|
|
Academic Article
|
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.
|
|
Academic Article
|
[American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease].
|
|
Academic Article
|
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center.
|
|
Academic Article
|
Infliximab as first-line therapy for severe Crohn's disease?
|
|
Academic Article
|
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.
|
|
Academic Article
|
Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease.
|
|
Academic Article
|
Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease.
|
|
Academic Article
|
The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies.
|
|
Academic Article
|
Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry.
|
|
Academic Article
|
Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy.
|
|
Academic Article
|
Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.
|
|
Academic Article
|
Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety.
|
|
Academic Article
|
Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines.
|
|
Academic Article
|
The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease.
|
|
Academic Article
|
Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab.
|
|
Academic Article
|
The Effect of Maternal Peripartum Anti-TNFa Use on Infant Immune Response.
|
|
Academic Article
|
Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-a4ß7 and anti-PD1 antibodies.
|
|
Academic Article
|
Maneuvering Clinical Pathways for Crohn's Disease.
|
|
Academic Article
|
Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.
|
|
Academic Article
|
Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease.
|
|
Academic Article
|
Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease.
|
|
Academic Article
|
Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
|
|
Academic Article
|
The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data.
|
|
Academic Article
|
Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis.
|
|
Academic Article
|
Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis.
|